Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Can Eli Lilly's Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.

Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

The post Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation? appeared first on 24/7 Wall St.. Eli Lilly (NYSE:LLY) presents mid-stage data on eloraTZP, a combination of eloralintide and tirzepatide, at a European Association for the Study of Diabetes symposium on…